Skip to content

Intratissue Electrolysis (EPI) is Effective in Deactivating Myofascial Trigger Points (MTrPs). (EPIEMG)

The Effectiveness of Intratissue Percutaneous Electrolysis in the Shortening of the Flexor Hallucis Brevis Caused by Myofascial Pain Syndrome. A Pre-post Study.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07351331
Acronym
EPIEMG
Enrollment
40
Registered
2026-01-20
Start date
2024-11-15
Completion date
2025-04-24
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myofascial Pain Syndrome (MPS)

Keywords

Percutaneous electrolysis, Dry needling, Myofascial pain syndrome, Flexor hallucis brevis, Electromyography, Pressure platform

Brief summary

Invasive physiotherapy techniques, such as Intratissue Percutaneous Electroly-sis (IPE), have numerous beneficial effects depending on the pathology being treated, in-cluding the deactivation of myofascial trigger points (MTP) caused by myofascial pain syndrome (MPS). The objectives are (1) evaluate the effectiveness of low intesity IPE treatment com-pared to DN on the shortening of FHB in patients with MPS, in 4 and 12 weeks evaluation, (2) assess the distribution of plantar pressures after the interventions and (3) evaluate the modification of FHB activation following the interventions.

Detailed description

Patients are divided into two intervention groups (IPE; n=18) and (DN; n=22). Before the intervention, variables of mean and maximum pressure are measured in all patients using a pressure platform, and neuromuscular activity is assessed through surface electromy-ography (sEMG). These measures are repeated at 4- and 12-weeks post-intervention. The results show efficacy in both techniques, with significant differences at both 4 weeks and 12 weeks in favor of the IPE group, both in plantar pressure distribution and muscular activity. The first measurement (week of November 25, 2024) is considered the baseline measurement since the subjects had not been previously intervened. Therefore, the measurement is first performed using the pressure platform and sEMG, followed by the intervention of DN or IPE based on the group to which the subjects were previously as-signed. At week 4 from the first measurement (week of December 23, 2024), the second data collection is conducted, using the same procedure as in the first measurement. At week 12 from the initial measurement (week of February 17, 2025), the third data collection takes place using the same procedure as the previous two, with the difference that in this final measurement there will be no intervention of DN or IPE.

Interventions

OTHERIntratissue Percutaneous Electroly

Three interventions were performed, the first in the initial week, after pressure and sEMG measurements, the second in week 4, and the third in week 12.

OTHERdry needling

Three interventions were performed, the first in the initial week, after pressure and sEMG measurements, the second in week 4, and the third in week 12.

Sponsors

Camilo Jose Cela University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* subjects with ages between 18 and 65 years, * hypersensitive spot within a taut band in FHB muscle. * pain upon stimulation of the MTP. * painful limit to the full range of motion

Exclusion criteria

* subjets who had bilateral LTP present. * who have had a lower limb injury or surgery within the last 6 months. * subjectss with active pathologies at the time of measurement in the lower limb. * subjectss with cognitive impairment. * subjectss with belonephobia or contraindications for the use of needles (oral anticoagulant therapy).

Design outcomes

Primary

MeasureTime frameDescription
mean pressures (MP)It was measured at the start of the protocol in week 1, in week 4 and in week 12.it is the average value of the pressure measured on a pressure platform, representing the general distribution of force per unit area across a surface (g/cm²)
maximum pressures (PMáx)It was measured at the start of the protocol in week 1, in week 4 and in week 12.it is the highest pressure value recorded on the pressure platform, indicating the point of greatest concentration of force per unit area on the evaluated surface.(g/cm²)
maximal voluntary contraction (MVC)It was measured at the start of the protocol in week 1, in week 4 and in week 12.The muscular activation is analyzed during 3 sets of 5 seconds of isometric contraction, against the resistance of the examiner's hand
dynamic muscular activation of the FHBIt was measured at the start of the protocol in week 1, in week 4 and in week 12.The subject's position is a protocol that has been previously explained to ensure correct measurement. The subject must walk for 20 seconds

Countries

Spain

Contacts

STUDY_DIRECTORMaría de Pedro Benito, PhD

Associate Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026